![Gene structure and exon organization of E6-AP.\
**(A)** The genomic structure of the coding region of E6-AP. The 10 exons that were reported in the first E6-AP gene structure study are indicated by closed boxes in green and numbered E1 to E10. The exons upstream of exon 1 are indicated by closed boxes in pink and are numbered U1 to U4. The three translation initiation sites (ATG) are shown. **(B)** A set of five E6-AP mRNAs with their potential protein isoforms (isoforms I, II, and III) that differ at their extreme amino-termini. 3'-region of exon 3 and exons 4-10 encode the *hect* domain. The E6-binding site is encoded within exon 3, and the active site cysteine is encoded within exon 10 (adapted from (Yamamoto et al., 1997)).](nrs06006.f1){#fig1}

![Schematic representation of the functional domains of E6-AP.\
E6-AP possesses five well-characterized functional domains: (i) a *hect* domain, (ii) an E6 binding domain, (iii) a p53 binding domain, (iv) two nuclear receptor interaction domains and (v) an activation domain, which have been represented with the amino acid numbers they correspond to. The three LXXLL motifs (NR box) are shown dispersed throughout the protein. Two of these motifs are located in the amino terminus and the third one is located within the carboxy terminus of the protein.](nrs06006.f2){#fig2}

![Proposed mechanism for the dynamic assembly of nuclear receptors and their coregulators during transcriptional activation.\
**Step 1:** In the absence of hormone, the NRs are in their inactive form, bound to chaperone proteins. In the presence of hormone, the NRs undergo conformational changes that result in the release of chaperones, which facilitate receptor dimerization and their recruitment to the promoter. **Step 2:** The negative regulators are cleared of the promoter via the ubiquitin proteasome pathway, followed by recruitment of coactivator complexes, general transcription factors (GTFs) and RNA polymerase II (Pol II) to the target gene promoter (Perissi et al., 2004). Some of the coactivators recruited to the promoter include ubiquitin proteasome enzymes like E6-AP and UBCH7 (Verma et al., 2004). **Step 3:** The preinitiation complex disassembles and the RNA Pol II escapes from the promoter, leading to transcriptional elongation. **Step 4:** Then the ubiquitin proteasome pathway degrades the nuclear receptor-transcription complex. According to this model, the active transcription depends on continuous reloading and degradation of the nuclear receptor-transcription complex, thus the ubiquitin-proteasome-dependent degradation and receptor-dependent transactivation are linked.](nrs06006.f3){#fig3}

###### Normalized expression of E6-AP in different tissues.

Normalized expression represents the relative expression of E6-AP level in different tissues and is \"normalized\" for the number of clones from each tissue that are included in UniGene.
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History
=======

The balance between protein synthesis and degradation is a critical and highly regulated process in a cell. Protein degradation is one of the many vital processes that are essential for cellular homeostasis. One of the most studied and well-understood systems involved in intracellular protein degradation is the ubiquitin proteasome pathway (UPP). In cells, a ubiquitous protein tag known as ubiquitin marks proteins targeted for degradation. Ubiquitin is a 76 amino acid polypeptide that is highly conserved among eukaryotes and is attached to the substrate (protein targeted for degradation) by a process called ubiquitination. Ubiquitination of proteins is carried out by a series of enzymes known as ubiquitin activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin protein ligase (E3). This results in the poly-ubiquitination of proteins that are then recognized by the 26S proteasome and are degraded \[[@r1]\]. E6-AP is a member of a family of proteins called *hect* (**h**omologous to **E**6-associated protein **c**arboxy-**t**erminal domain) domain E3 ligases that share carboxy terminal sequence homology with each other \[[@r2]; [@r3]\]. This growing family of *hect* domain containing proteins has several members that have been shown to function as E3 ubiquitin ligases through their ability to form thioester bonds with ubiquitin.

The 100 kDa cellular protein E6-AP (UBE3A) was first identified as a protein that interacts with the E6 protein of human papilloma virus (HPV) type 16 and 18 \[[@r3]\]. E6 is a viral oncogenic protein that forms a complex with E6-AP and then this E6/E6-AP complex binds to p53 and facilitates its ubiquitination and degradation through the UPP \[[@r3]\]. Although the binding of E6-AP to E6 was required to induce ubiquitination of p53, it was not clear whether E6-AP was actively involved in the ubiquitination of p53. In 1993, Martin *et al.* demonstrated that the ubiquitination of p53 requires the E6/E6-AP complex and that this complex provides the E3 ligase activity \[[@r3]\]. Later, the same group also showed that E6-AP has ubiquitin-protein ligase activity in the absence of viral E6 protein. In addition to E6-AP, a variety of other E3-ligases have also been shown to promote p53 degradation including Mdm2 (murine double minute 2), COP1 (constitutively photomorphogenic 1), PIRH2 (p53-induced-RING-H2), etc \[[@r47]; [@r48]; [@r46]\]. Huibregtse *et al.* identified two E6-AP homologous; a 100 kDa protein in rat and a 95 kDa protein in yeast (RSP5) with E3-ubiquitin protein ligase activity \[[@r5]\].

In 1999, Nawaz *et al.* demonstrated that E6-AP can also act as a coactivator for steroid hormone receptors (SHRs) such as progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), retinoic acid receptor-α (RAR-α) and thyroid hormone receptor (TR). It was also shown that the ubiquitin ligase function of E6-AP is not required for the coactivation function of E6-AP and the *hect* domain of E6-AP is not necessary for the ability of E6-AP to interact with SHR and coactivate SHR function. This indicated that E6-AP possesses two independent, separable functions; a coactivation function and an ubiquitin-protein ligase activity \[[@r104]\]. The same year, it was also shown that a genetic disorder, Angelman Syndrome (AS), is caused by the absence of a functional maternal copy of the UBE3A gene that codes for E6-AP \[[@r7]; [@r8]\]. It was concluded that the loss of ligase activity, and not the coactivator function, is responsible for the clinical manifestation of this syndrome \[[@r104]\].

Structure and organization of the UBE3A/E6-AP gene
==================================================

The UBE3A gene that encodes E6-AP is located in the q11-q13 region of chromosome 15 in humans and the UBE3A locus is confined to chromosome 7 in mouse; 7 28.65 cM (http://source.stanford.edu). The E6-AP coding region extends over 60 kilo base pairs (kb) and the length of E6-AP mRNA is approximately 5 kb, with 10 exons. Characterization of the E6-AP gene structure and E6-AP cDNAs has shown that there are at least four different mRNA variants. Sequence analysis revealed five mRNA subtypes 1-5; these subtypes vary in their upstream exons (U1-U4) due to differential splicing. Subtype-1 cDNA contains exons U1, U2, U3 and U4, whereas subtype-2 cDNA lacks exon U4. In subtype-3, exons U3 and U4 are skipped and a potential start codon appears within exon U2. mRNA subtypes 4 and 5 lack exon U4 and exon U3, respectively. These five different cDNA subtypes code for three potential E6-AP protein isoforms (I, II and III), differing in size by as much as 22 amino acids. E6-AP isoform I is coded by cDNA subtypes 1, 4 and 5, while E6-AP isoforms II and III are coded by cDNA subtypes 2 and 3, respectively. Isoform I corresponds to the open reading frame for E6-AP, while isoforms II and III have an additional 20 and 23 amino acids, respectively, at their amino-termini. These additional amino acids do not affect the known functions of E6-AP. The cDNA subtype 2 encodes the longest isoform of the E6-AP protein, isoform II ([Figure 1](#fig1){ref-type="fig"}). The physiological function of the different protein isoforms is not yet known. The *hect* domain is encoded by the last eight exons starting from the 3' region of exon 3 through exon 10. The E6-binding site is encoded by exon 3 and the active site cysteine residue, which accepts ubiquitin from the E2 ubiquitin-conjugating enzyme, is encoded within exon 10 \[[@r12]; [@r11]\].

Two E6-AP (UBE3A) pseudogenes, UBE3AP1 and UBE3AP2, have also been identified. Both pseudogene sequences revealed a 90-95% nucleotide identity to that of E6-AP. UBE3AP1 and UBE3AP2 were mapped to chromosomes 2 and 21, respectively, but there is no evidence for the expression of these pseudogenes \[[@r12]\].

Functional domains of E6-AP and E6-AP interacting proteins
==========================================================

Human E6-AP consists of 865 amino acids, while the murine homolog is slightly longer with 885 amino acids, and these two proteins are 99% similar. E6-AP possesses five well-characterized functional domains: (i) a *hect* domain, (ii) an E6 binding domain, (iii) a p53 binding domain, (iv) three nuclear receptor interaction domains and (v) an activation domain \[[@r13]; [@r104]\].

The carboxy terminal 350 amino acids form the conserved *hect* domain of E6-AP, a region of homology shared by several proteins structurally and functionally related to E6-AP \[[@r5]\]. The *hect* domain of E6-AP has a 40 kDa conserved carboxy-terminal catalytic domain that has at least four biochemical functions: 1) it binds to specific E2 ubiquitin-conjugating enzymes like UbcH7, UbcH5B and UbcH8; 2) it accepts ubiquitin from E2 enzyme, forming a ubiquitin-thioester intermediate with its active site cysteine \[[@r14]\]. A conserved cysteine residue at position 833 in the *hect* domain confers the ubiquitin ligase activity of E6-AP. *In vitro* studies have shown that the mutation of cysteine 833 residue to alanine or serine renders it unable to form a thioester bond with ubiquitin; 3) it transfers ubiquitin to the ε-amino groups of lysine side chain on the substrate by catalyzing the formation of an isopeptide bond; and 4) it transfers additional ubiquitin molecules to the growing end of the multi-ubiquitin chain \[[@r15]; [@r16]\].

E6-AP has been shown to function as an E3 ligase in the ubiquitination of p53 in cooperation with HPV E6 protein \[[@r17]\]. The viral E6 protein acts as an adaptor between p53 and E6-AP \[[@r13]\]. This E6-dependent binding of p53 to E6-AP involves amino acids 280-781 of E6-AP, which form the central leucine-rich core that is crucial for the biological function and structural stability of E6-AP. An 18 amino acid region of E6-AP, from 391-408, has been shown to be necessary and sufficient for binding to E6 \[[@r18]\]. This sequence was later characterized as a leucine-rich peptide, LQELL, which is a signature LXXLL motif (a receptor interacting motif) \[[@r17]; [@r7]; [@r3]; [@r19]\]. An essential intermediate step in E6-AP-dependent ubiquitination is the formation of a thioester complex between E6-AP and ubiquitin-conjugating enzymes. In the case of ubiquitin-conjugating enzyme UbcH5B, the implicated binding site corresponding to amino acids 521-679 of E6-AP, falls within the central leucine-rich core of E6-AP ([Figure 2](#fig2){ref-type="fig"}). The region of E6-AP involved in complex formation with UbcH7 and UbcH8 was mapped to its *hect* domain \[[@r15]; [@r20]\]. Recently, Mani *et al.* identified AIB1 (amplified in breast cancer 1)/SRC-3 (steroid receptor coactivator-3) as a substrate for E6-AP-mediated ubiquitination and established that the steady-state level of AIB1 is regulated by E6-AP. The interaction between E6-AP and AIB1 is mediated through the carboxy terminus of AIB1 \[[@r21]\].

Since its identification as a coactivator of SHRs, E6-AP has been shown to interact with a variety of other proteins, which includes SHRs and other coregulators. E6-AP contains 3 consensus receptor-interacting LXXLL motifs. Two of these motifs are located in the amino terminus and the third one is located within the carboxy terminus of the protein. After its characterization as a PR-interacting protein, E6-AP has also been shown to interact with other SHRs, such as AR and ER, and these interactions are enhanced in the presence of appropriate hormone \[[@r97]; [@r106]\]. Nawaz *et al.* showed that E6-AP not only interacts with different SHRs, it also contains an intrinsic, transferable activation domain that extends from amino acids 170 to 680 \[[@r104]\]. In addition to SHRs, Dhananjayan *et al.* have recently shown that E6-AP also interacts with a WW-domain binding protein -2 (WBP-2), and further investigation revealed that E6-AP and WBP-2 had additive effect on ER and PR coactivation when both of them were coexpressed \[[@r97]\].

Expression and sub-cellular localization
========================================

E6-AP is ubiquitously expressed in various tissues ([Table 1](#table-fn1){ref-type="table"}) and (http://source.stanford.edu). The E6-AP protein was found to be predominantly localized in the cytoplasm, and to a lesser extent in the nucleus, by using fluorescence microscopy \[[@r24]\]. A recent study using Ube3aYFP knock-in indicated that maternal-derived Ube3a was expressed in most brain regions, including hippocampus, cortex, thalamus, olfactory bulb and cerebellum \[[@r51]\]. The paternal Ube3a is expressed only at a basal level in these brain regions. They also showed that the maternally-derived E6-AP localizes to the nucleus, growth cone and pre- and postsynaptic compartments in the hippocampal neurons, which implies that E6-AP may regulate the development and/or function of synapses \[[@r51]\].

Function of E6-AP in the cell
=============================

The two well-characterized functions of E6-AP in the cell are 1) regulation of SHR-dependent gene transcription and 2) an E3 ubiquitin ligase activity.

Role of E6-AP in transcription
------------------------------

After its cloning and characterization as a PR-interacting protein, E6-AP has been shown to interact with and coactivate the hormone-dependent transactivation function of several steroid hormone receptors such as ER, AR, PR, GR, TR and RAR. Furthermore, E6-AP reverses the squelching between ER and PR, and it also contains an intrinsic activation function in its amino-terminal domain \[[@r104]\]. Additionally, it has been shown that the catalytic function located within the *hect* domain of E6-AP is not necessary for the ability of E6-AP to interact with and coactivate steroid hormone receptor functions.

Chromatin immunoprecipitation (ChIP) assay is used to reveal the recruitment of transcription factors and coregulators to their target genes and to study the time-dependent recruitment of the transcription machinery to the promoter regions of target genes. E6-AP has been shown to be recruited to the promoter region of the AR-responsive gene, PSA, in a hormone-dependent manner \[[@r106]\]. Furthermore, ChIP experiments have indicated that E6-AP is recruited to the estrogen-responsive pS2 promoter and that E6-AP is cyclically associated with the pS2 promoter with a periodicity of 40 min. Re-ChIP analysis of the complex showed that E6-AP is associated with the p300-CBP/SRC-1 complex at the pS2 promoter \[[@r50]\]. This strongly suggests that E6-AP is recruited to the hormone-responsive promoters *in vivo* and regulates hormone-dependent gene expression.

Recent studies have demonstrated that E6-AP is required for transactivation of the human telomerase reverse transcriptase (hTERT) promoter and is recruited to this promoter by the human papilloma virus E6 oncoprotein. In normal cells, telomerase activity is regulated by transcriptional control of the hTERT promoter \[[@r25]\]. It has been found that in differentiated epithelial cells that have lost anchorage, hTERT is transcriptionally repressed by the recruitment of histone deacetylase to the hTERT promoter. Inhibition of HDAC1 and induction of histone acetylation is sufficient for activation of hTERT promoter activity in normal human cells. In 2006, James *et al.* provided evidence that the hTERT promoter is activated by viral E6 protein in association with acetylation of histone H3 at the hTERT promoter. Acetylation of H3 and activation of the hTERT promoter by E6 is dependent on E6-AP and is enhanced by knockdown of p300 (E1A binding protein p300). More importantly, E6-AP knock-out mouse cells and small interfering RNA-mediated knock-down of E6-AP in human cell lines demonstrated that E6-AP is required for E6-mediated hTERT promoter transactivation in both mouse and human cells \[[@r26]\].

Role of E6-AP as an ubiquitin protein ligase
--------------------------------------------

E6-AP was originally discovered as an ubiquitin ligase that interacts with the E6 protein of human papilloma virus and, E6/E6-AP complex targets p53 for ubiquitination and degradation via the UPP \[[@r3]\]. Since then, numerous other cellular proteins have been reported to interact with E6, and some of these have also been reported to be targeted for degradation in an E6-AP-dependent manner. Some examples include BAK (Bcl-2 homologous antagonist/killer), c-MYC, Mcm-7 (minichromosome maintenance protein 7) and hScrib (the human analogue of the *Drosophila* Scribble tumor suppressor protein) \[[@r28]; [@r25]; [@r27]\]. In an attempt to determine if E6-AP could function as an ubiquitin ligase independent of E6, Kumar *et al.* screened for E6-independent E6-AP substrates that were marked for degradation. In this screen they showed that a DNA repair protein, HHR23A (human homologue of the yeast DNA repair protein RAD23), interacts with E6-AP and is efficiently ubiquitinated in an E6-AP-dependent, but E6-independent manner *in vitro*. Furthermore, their data also suggested that E6-AP-mediated ubiquitination of HHR23A may be important in regulating its function in DNA repair and cell cycle progression, suggesting a physiological role for E6-AP-mediated ubiquitination \[[@r14]; [@r29]\].

Subsequently, it was shown that E6-AP could target itself for degradation *in vitro* \[[@r30]\]. This was corroborated *in vivo* by the observation that under conditions of overexpression of E6-AP, it efficiently promoted its own poly-ubiquitination and degradation via the UPP. Such self-ubiquitination has been proposed to result from inter-molecular transfer of ubiquitin on E6-AP molecules that are not bound to substrate proteins. This may be a regulatory mechanism to control the intracellular levels of E6-AP by inactivating and degrading unbound E6-AP molecules \[[@r31]; [@r30]\].

The characterization of E6-AP as a coactivator for SHRs, along with the observations that several nuclear receptors are ubiquitinated and degraded in the course of their transcriptional activities, suggests that ubiquitin proteasome-mediated protein degradation plays a crucial role in eukaryotic transcription ([Figure 3](#fig3){ref-type="fig"}) \[[@r33]; [@r101]\]. The evidence implicating the 26S proteasome in the control of nuclear receptor stability was provided by proteasome inhibition studies using MG132, lactacystin, and other proteasome inhibitors. Proteasome inhibition significantly diminished the ligand-induced transcriptional activity of most of the NRs, which includes AR, ER, PR, RAR-α, TR, peroxisome proliferator-activated receptor (PPAR) and retinoid X receptor (RXR) \[[@r33]; [@r101]; [@r102]; [@r103]\]. Because of the broad cellular effects of proteasome inhibitors, it is difficult to directly link their functional outcome to the stability of the receptor alone. Thus, considerable effort is being focused on determining the specific E3 ligases involved in targeting the receptors for proteolysis. Although the identity of the E3 ligase(s) involved in ER-α proteolysis has remained controversial and elusive, there is evidence correlating ER-α and AR protein stability to the level of E6-AP expression \[[@r100]; [@r106]\]. The interaction of E6-AP with the ER-α and AR and its recruitment to their target gene promoters supports the idea that E6-AP might be one of the E3 ligases responsible for the ubiquitination and degradation of ER-α and AR \[[@r97]; [@r106]; [@r50]\]. This notion was confirmed in the prostate glands of E6-AP null mice, where, although the level of AR protein was elevated, the level of an AR target protein, Probasin, was decreased. Despite the identification of E6-AP as a modulator of receptor transcription function, its activity in relation to ubiquitination and proteolysis of receptors is yet to be determined.

In 2006, Mani *et al.* reported the requirement of the E6-AP for the degradation of a nuclear receptor coactivator, AIB1 \[[@r21]\]. This study raises the intriguing possibility that the clearance of coactivators from the enhancer/promoter may enable the sequential interaction of an activated receptor with a newly-assembled coactivator complex \[[@r105]\].

All these examples show that E6-AP, a component of the ubiquitin-proteasome pathway, could orchestrate the dynamics of NR-mediated transcription by regulating the degradation of the transcriptional complexes \[[@r37]\].

Biological role of E6-AP
========================

The physiological role of E6-AP was examined using mice lacking the E6-AP gene (E6-APKO) \[[@r38]\]. E6-APKO mice are viable, but exhibit several interesting phenotypic changes. Postnatal viability is reduced in E6-AP null homozygotes. Heterozygous mice lacking a maternal copy of E6-AP exhibit numerous adverse symptoms such as motor dysfunction and inducible seizures, reminiscent of AS in humans. In addition, in these mice, the cytoplasmic levels of p53 are grossly elevated in Purkinje cells and some hippocampal pyramidal neurons, which may be responsible for the observed deficiencies in context-dependent learning and hippocampal long-term potentiation. These results suggest that E6-AP is required for the proper development of neuronal synapses in the central nervous system \[[@r38]; [@r7]\].

Smith *et al.* have shown that E6-AP KO mice of both sexes are less fertile than wild type mice, due to the reduced size of their gonads. Consistent with this observation, defects in sperm production and ovulation were also seen. Moreover, the hormonal induction of growth of the prostate and uterine glands by testosterone and estradiol was significantly reduced in these mice \[[@r107]\]. Recent studies from our laboratory have reported that the deletion of E6-AP in male mice attenuates the growth and development of the prostate gland. This effect was brought about by a partial loss of signaling in the PI3K (phosphoinositide 3-kinase)/Akt mitogenic pathway, which is regulated by E6-AP. The levels of PI3K and both total and phosphorylated Akt are much reduced in E6-AP null prostates. In contrast, the steady state level of RhoA, which negatively regulates AR function and PI3K-Akt signaling, was shown to be elevated in prostate tissue. Furthermore, the levels of p53 and apoptosis-inducing proteins such as Bax, and active caspases are increased in the E6-AP null prostate, accompanied by an increase in apoptosis. Collectively, these data suggest that E6-AP controls the growth of prostate gland by modulating several major cellular pathways, such as AR signaling, PI3K/AKT signaling pathway, RhoA signaling pathway and p53-mediated apoptosis \[[@r106]\]. Taken together, these results implicate E6-AP as an important molecule involved in various aspects of reproduction and therefore extend the physiological role of this protein to tissues outside the central nervous system.

Alteration of E6-AP expression in human pathology
=================================================

Clinical manifestations of mutation in the UBE3A gene locus
-----------------------------------------------------------

The E6-AP (UBE3A) locus is imprinted in certain regions of the brain such that only the maternal copy of the gene is expressed \[[@r8]\]. Angelman Syndrome is caused by maternal deletion of chromosome 15q11-q13, paternal uniparental disomy (pUPD) of chromosome 15, imprinting defects or by loss of function mutations in the UBE3A locus that encodes E6-AP \[[@r7]; [@r8]\]. AS is a severe neurological disorder characterized by moderate to severe mental retardation, absence of speech, tremors, ataxia, abnormal gait, inappropriate laughter, sleep disturbance and seizures \[[@r40]\]. There are 29 different mutations in E6-AP that are reported to cause AS, including 17 frame shifts, 5 nonsense, 3 missense and one each of single amino acid insertion, single amino acid deletion, splicing and stop codon \[[@r41]\]. Subsequent research showed that there is a strong correlation between AS and loss of E3 ubiquitin ligase activity of E6-AP. Since E6-AP is an ubiquitin ligase, it is likely that the improper regulation of E6-AP substrate(s) causes AS, although no disease-relevant E6-AP targets have yet been identified. However, data from E6-AP knockout mice suggests that p53 might be one of the substrates for E6-AP and loss of p53 degradation due to the lack of E6-AP may lead to the development of AS \[[@r38]\].

The paternal deficiency of the same region, ch15q11-q13, causes Prader-Willi Syndrome (PWS). Like AS, PWS is also characterized by defective neurological, developmental and behavioral phenotypes. PWS is characterized by hypotonia, respiratory distress and small stature \[[@r42]\].

Deregulated expression of E6-AP in tumorigenesis
------------------------------------------------

Recently, the role of coactivators in tumor development and progression has gained increasing attention. In fact, the overexpression of nuclear receptor coactivators, including AIB1, SRA (steroid receptor RNA activator) and AIB3 (amplified in breast cancer 3) has been implicated in human breast cancers \[[@r99]\]. Studies from our lab have demonstrated that the expression of E6-AP protein is decreased in human invasive breast and prostate carcinomas compared with their adjacent normal tissues. This down-regulation of E6-AP is accompanied by the elevation of ER in breast and AR in prostate carcinomas \[[@r100]\]. Furthermore, *in vivo* data from E6-AP-knockout animals indicated that the expression levels of ER and AR are increased in E6-AP-null mammary and prostate glands, respectively, when compared with that of normal control animals, suggesting that E6-AP modulates the protein levels of ER in breast and AR in prostate glands \[[@r100]; [@r106]\].

Conclusion
==========

E6-AP was one of the ubiquitin proteasome pathway enzymes that were characterized as a coactivator of NRs. The interaction of E2-ubiquitin conjugating enzyme, E3-ubiquitin ligase enzyme and components of the proteasomal subunit with the transcription machinery and their recruitment to the promoter reinforces the hypothesis that the degradation of nuclear receptors could be linked to transcriptional activation and may be necessary for efficient transcriptional activity. Although a significant amount of work has been done on E6-AP to determine its mechanism of action and to establish its biological relevance, several critical questions still remain unanswered. Further work is warranted to unravel the mechanism of action of E6-AP and to understand its function in SHR signaling and tumorigenesis.
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